Semaglutide vs Retatrutide
A side-by-side comparison of Semaglutide and Retatrutide, including efficacy data, side effects, dosing, and cost.
Feature
Semaglutide
Retatrutide
Drug Class
GLP-1 receptor agonist
GLP-1, GIP, and glucagon triple receptor agonist
Brand Names
Ozempic, Wegovy, Rybelsus
None yet
Form
Once-weekly injection (Ozempic, Wegovy) or daily tablet (Rybelsus)
Once-weekly injection (investigational)
Dosing
0.25 mg → 0.5 mg → 1 mg → 2 mg (weekly injection); 3 mg → 7 mg → 14 mg (daily tablet)
1 mg → 2 mg → 4 mg → 8 mg → 12 mg (weekly, clinical trial dosing)
FDA Approval
Type 2 diabetes (Ozempic, Rybelsus); Chronic weight management (Wegovy)
Not yet FDA approved (Phase 3 trials ongoing)
Efficacy
Average 15-17% body weight loss over 68 weeks (STEP trials)
Average 24% body weight loss over 48 weeks (Phase 2 trials)
Cost
$900-$1,400/month without insurance
Not yet available commercially
Semaglutide Side Effects
- •Nausea
- •Vomiting
- •Diarrhea
- •Constipation
- •Abdominal pain
- •Headache
Retatrutide Side Effects
- •Nausea
- •Diarrhea
- •Increased heart rate
- •Vomiting
- •Constipation
Which one should you choose?
The best medication depends on your health goals, insurance coverage, and how your body responds. Semaglutide is a glp-1 receptor agonist, while Retatrutide is a glp-1, gip, and glucagon triple receptor agonist, which can affect both efficacy and side effects.
Always consult your healthcare provider before starting or switching medications.